A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Lymphoma

Interventions

DRUG: CC-220
DRUG: Rituximab
DRUG: Obinutuzumab

Sponsor

Celgene